SAMSUNG-ELECTRONICS
17.1.2023 10:06:47 CET | Business Wire | Press release
Samsung Electronics Co., Ltd., a world leader in advanced semiconductor technology, today introduced its latest 200-megapixel (MP) image sensor, the ISOCELL HP2, with improved pixel technology and full-well capacity for stunning mobile images in tomorrow’s premium smartphones.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230117005554/en/
Samsung Introduces the 200-Megapixel Image Sensor for the Ultimate High Resolution Experience in Flagship Smartphones (Graphic: Business Wire)
"The Samsung ISOCELL HP2 harnesses Samsung's high-resolution image sensor technologies and know-how at the cutting edge for epic details," said JoonSeo Yim, Executive Vice President of Sensor Business Team at Samsung Electronics. "Our leadership comes from innovative pixel technologies that allow our sensors to go beyond the number and size of pixels. We will continue to open new horizons and solidify our presence in the expanding ultra-high-resolution sensor market."
The ISOCELL HP2 packs 200-million 0.6-micrometer (μm) pixels in a 1/1.3” optical format, a sensor size that is widely used in 108MP main smartphone cameras. This enables consumers to enjoy even higher resolutions in the latest high-end smartphones without larger camera bumps in their devices.
With Samsung’s advanced pixel-binning technology, Tetra2pixel, the HP2 adds more versatility to the camera as it simulates different pixel sizes to accommodate varying lighting levels. When in low-lit environments, the sensor transforms either into a 1.2μm 50MP or 2.4μm 12.5MP image sensor by binding four to 16 neighboring pixels. For fuller 8K video, approximately at 33MP, the HP2 switches to 1.2μm 50MP mode to minimize cropping and capture more of the scene. Filming 8K at 30 frames-per-second (fps), a wide field of view along with bigger pixel size can produce sharp cinematic videos.
Washed out pictures from brightly lit environments can be significantly reduced with the HP2, thanks to Samsung’s new Dual Vertical Transfer Gate (D-VTG) technology. In a photo diode within each pixel, a voltage transfer gate is placed on the bottom to transport electrons from the pixels to the logic layer. With high precision, D-VTG adds a second transfer gate in the pixel, boosting the pixel’s full-well capacity by more than 33 percent. With more electrons stored and efficient signal transfers, this method can reduce overexposure and enhance color reproduction, especially in bright light conditions
In low-lit settings, the HP2’s auto-focusing is taken to the next level with Super QPD, which allows the sensor to use all its 200-million pixels for focusing agents. The ample amount of focusing agents are grouped by four adjacent pixels to recognize both horizontal and vertical pattern changes that delivers faster and more accurate auto-focusing. Utilizing the rich pattern data along with the sheer number of reference points, the new sensor is capable of fast auto-focusing, even in a dimly lit environment.
For superb HDR performance, Samsung is introducing the DSG feature for the first time in 50MP mode which applies two separate conversion values to the analog signal received at the pixel level. In addition, the Smart-ISO Pro, an HDR solution that merges different levels of ISO readouts from a single exposure, allows the camera to take 12.5MP images and 4K at 60fps video in HDR.
The Samsung ISOCELL HP2 has entered mass production.
About Samsung Electronics Co., Ltd.
Samsung inspires the world and shapes the future with transformative ideas and technologies. The company is redefining the worlds of TVs, smartphones, wearable devices, tablets, digital appliances, network systems, and memory, system LSI, foundry and LED solutions. For the latest news, please visit the Samsung Newsroom at news.samsung.com.
# # #
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230117005554/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
